Skip to content
home
  • Capabilities
    • CARDIOVASCULAR SYSTEM
    • CENTRAL NERVOUS SYSTEM
    • DERMATOLOGY
    • GASTRO-INTESTINAL SYSTEM
    • INFLAMMATION
    • LIVER & HEPATIC SYSTEM
    • ONCOLOGY
    • OBESITY & METABOLIC DISORDER
    • PAIN
    • PHARMACOKINETICS
    • PREDICTIVE TOXICITY
    • RESPIRATORY SYSTEM
    • SAFETY REGULATORY PACKAGE
    • THROMBOSIS
    • UROGENITAL SYSTEM
    • MEDICAL DEVICES
  • CATALOG
  • News and Publications
  • About
    • ABOUT US
    • CAREERS
    • BIOMARKER ASSAYS
    • CELL & TISSUE BANKS
    • FORMULATION ANALYSIS
    • IMAGE PROCESSING
    • TECHNICAL SKILLS
    • TECHNICAL CAPABILITIES
  • Contact Us
Menu Close
  • Capabilities
    • CARDIOVASCULAR SYSTEM
    • CENTRAL NERVOUS SYSTEM
    • DERMATOLOGY
    • GASTRO-INTESTINAL SYSTEM
    • INFLAMMATION
    • LIVER & HEPATIC SYSTEM
    • ONCOLOGY
    • OBESITY & METABOLIC DISORDER
    • PAIN
    • PHARMACOKINETICS
    • PREDICTIVE TOXICITY
    • RESPIRATORY SYSTEM
    • SAFETY REGULATORY PACKAGE
    • THROMBOSIS
    • UROGENITAL SYSTEM
    • MEDICAL DEVICES
  • CATALOG
  • News and Publications
  • About
    • ABOUT US
    • CAREERS
    • BIOMARKER ASSAYS
    • CELL & TISSUE BANKS
    • FORMULATION ANALYSIS
    • IMAGE PROCESSING
    • TECHNICAL SKILLS
    • TECHNICAL CAPABILITIES
  • Contact Us

QT interval prolongation and cardiac risk assessment for novel drugs

Home » QT interval prolongation and cardiac risk assessment for novel drugs

QT interval prolongation and cardiac risk assessment for novel drugs

  • Post published:October 22, 2003
  • Post category:Cardiovascular system / Publications

QT interval prolongation and cardiac risk assessment for novel drugs

PORSOLT_QT-interval-prolongation-and-cardiac-risk-assessment-for-novel-drugsDownload

Read more articles

Previous PostPrulifloxacin in-vitro and in-vivo assessment of cardiac risk
Next PostPrimary Observation (Irwin) Test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function.

You Might Also Like

The usefulness of non-human primates in central nervous system safety pharmacology

The usefulness of non-human primates in central nervous system safety pharmacology

July 26, 2013
Anxiolytic-like  effects  of  the  prototypical  meta botropic  glutamate  receptor  5   antagonist  2-methyl-6-( phenylethynyl)  pyridine  in  rodents.

Anxiolytic-like effects of the prototypical meta botropic glutamate receptor 5 antagonist 2-methyl-6-( phenylethynyl) pyridine in rodents.

February 29, 2000
Models of cardiovascular disease: measurement of arrhythmogenic/antiarrhythmic activity in the guinea pig.

Models of cardiovascular disease: measurement of arrhythmogenic/antiarrhythmic activity in the guinea pig.

October 22, 2009

Categories

Archives

Recent Posts

  • Collaboration between Porsolt, GlioCure and the University of Angers to fight Glioblastoma
  • Boucle du diabète 2022
  • Sales & Marketing June 2022
  • Meet Coralie at the Lab dating Vendôme 2022 and explore your future possibilities at Porsolt !
  • Great opportunity for Porsolt to finally get back to in-person conferences

News & Updates

Sign up to get all the latest news and updates delivered directly to your email
Email is required Email is not valid
This field is required
Thanks for your subscription.
Failed to subscribe, please contact admin.

Follow Us

© Copyright - PORSOLT 2022